CASI PHARMACEUTICALS, INC. (CASIF) Return on equity 2020–2024
CASI PHARMACEUTICALS, INC. (CASIF) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-2120.9%FY2024 · since FY2020: -59.2% → -2120.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -2120.9% | -2009.3 pp |
| FY2023 | -111.6% | -19.6 pp |
| FY2022 | -92.0% | -48.6 pp |
| FY2021 | -43.4% | +15.8 pp |
| FY2020 | -59.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice